Variable | Description | No. of patients | % of patients | HR | 95% CI | P |
Categoric | ||||||
PSA changes after 6 wk* | Stable | 35 | 30 | 1.00 | ||
Response | 45 | 40 | 0.47 | 0.28–0.80 | 0.006 | |
Progression | 34 | 30 | 3.79 | 2.09–6.89 | <0.001 | |
Gleason score at diagnosis | <8 | 40 | 35 | 1.00 | ||
≥8 | 74 | 65 | 0.67 | 0.40–1.11 | 0.12 | |
M status at diagnosis | M0 | 75 | 64 | 1.00 | ||
M1 | 39 | 36 | 1.78 | 1.05–3.02 | 0.03 | |
Chemotherapy status | Before chemotherapy | 26 | 23 | 1.00 | ||
After chemotherapy | 88 | 77 | 1.75 | 1.02–3.00 | 0.04 | |
Site of metastases | Nonvisceral | 78 | 68 | 1.00 | ||
Visceral | 36 | 32 | 1.28 | 0.79–2.07 | 0.31 | |
ECOG performance status | 0 | 27 | 24 | 1.00 | ||
1 | 79 | 69 | 1.03 | 0.63–1.66 | 0.90 | |
2 | 8 | 7 | 1.27 | 0.53–3.08 | 0.58 | |
Pain status at baseline† | Asymptomatic disease | 42 | 37 | 1.00 | ||
Symptomatic disease | 73 | 63 | 0.87 | 0.55–1.37 | 0.55 | |
Continuous | ||||||
Time since diagnosis (log10 y) | Median, 0.81 | IQR, 0.57–1.05 | 0.61 | 0.27–1.37 | 0.23 | |
PSA (log10 ng/mL) | Median, 2.13 | IQR, 1.54–2.54 | 1.05 | 0.76–1.44 | 0.76 | |
LDH (log10 U/L) | Median, 2.42 | IQR, 2.33–2.54 | 0.35 | 0.08–1.38 | 0.13 |
↵* Stable = PSA decline of <30% and <25% increase; response = PSA decline of ≥30%; progression = PSA increase of ≥25%.
↵† Asymptomatic disease = no pain and no opioid use at baseline; symptomatic disease = presence of pain or use of opioids for cancer-related pain at treatment initiation.
ECOG = Eastern Cooperative Oncology Group; LDH = lactate dehydrogenase; tALP = total alkaline phosphatase.